James Shannon
Président chez PROQR THERAPEUTICS N.V.
Fortune : 222 849 $ au 30/04/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Theresa Heggie | F | 63 | 1 ans | |
Domenico Valerio | M | 67 |
Leyden Laboratories B.V.
Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | 12 ans |
Gerard J. Platenburg | M | 60 | 12 ans | |
Ronald H. P. Brus | M | 61 |
Leyden Laboratories B.V.
Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation.
Impatients NV
Impatients NV Miscellaneous Commercial ServicesCommercial Services Impatients N.V. operates an online platform for drug innovations. It provides physicians and patients that are excluded from clinical trials access to drugs in development via early access programs. The company was founded by Ronald Brus, SJaak Vink, Govert J. Schouten, Witt Jan, Erdem Yavuz, and René Beukema in 2012 and is headquartered in Amsterdam, the United Kingdom. | 12 ans |
Steven Binder | M | 61 | 7 ans | |
Kent Kresa | M | 86 | 20 ans | |
Michael Castagna | M | 47 | 8 ans | |
Rosabel Realica Alinaya | F | 63 | 21 ans | |
René Beukema | M | 60 | 8 ans | |
Daniel de Boer | M | 41 | 12 ans | |
Sheila Sponselee | F | - | 4 ans | |
Stephen L. Bandak | M | 74 |
The Royal College of Physicians
| 47 ans |
Koenraad Wiedhaup | M | - |
Leyden Laboratories B.V.
Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | - |
David Thomson | M | 57 | 22 ans | |
Anthony Hooper | M | 69 | 4 ans | |
Sabrina Kay | M | 61 | 4 ans | |
Alison Lawton | F | 62 | 10 ans | |
Jennifer Grancio | F | 52 | 4 ans | |
Christine Mundkur | F | 55 | 6 ans | |
Bart Filius | M | 53 | 5 ans | |
Peter Richardson | M | 64 |
The Royal College of Physicians
| 8 ans |
Michael Friedman | M | 80 | 21 ans | |
Ronald Consiglio | M | 80 | 21 ans | |
Jaap Goudsmit | M | 73 |
Leyden Laboratories B.V.
Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | - |
Harry Solomon | M | 87 |
The Royal College of Physicians
| - |
Steve Knowles | M | - |
The Royal College of Physicians
| - |
Joseph Kocinsky | M | 60 | 21 ans | |
Henry Y. Pan | M | 77 |
The Royal College of Physicians
| - |
Stephen Knight | M | 63 |
Leyden Laboratories B.V.
Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | - |
Helen Torley | M | 61 |
The Royal College of Physicians
| - |
Man Yung Cheng | M | 74 |
The Royal College of Physicians
| 44 ans |
Alexandra Sinclair | M | - |
The Royal College of Physicians
| - |
Ravi Rao | M | 55 |
The Royal College of Physicians
| - |
Karin Rosen | M | 57 | 4 ans | |
Richard Philipson | M | 60 |
The Royal College of Physicians
| - |
Lesley Russell | M | 63 |
The Royal College of Physicians
| 37 ans |
Stuart Ungar | M | 80 |
The Royal College of Physicians
| - |
Karen Atkin | M | 58 |
The Royal College of Physicians
| - |
Monica Shaw | M | 46 |
The Royal College of Physicians
| - |
Bipin Mistry | M | - |
The Royal College of Physicians
| - |
Jane Gonnerman | F | - | 3 ans | |
Marnix Ploeg van der | M | - |
Impatients NV
Impatients NV Miscellaneous Commercial ServicesCommercial Services Impatients N.V. operates an online platform for drug innovations. It provides physicians and patients that are excluded from clinical trials access to drugs in development via early access programs. The company was founded by Ronald Brus, SJaak Vink, Govert J. Schouten, Witt Jan, Erdem Yavuz, and René Beukema in 2012 and is headquartered in Amsterdam, the United Kingdom. | 8 ans |
Christopher Burton | M | - |
The Royal College of Physicians
| - |
Ian Gourley | M | - |
The Royal College of Physicians
| - |
Mike Anderson | M | - |
The Royal College of Physicians
| - |
Pyarelal Baburam Tiwari | M | 77 |
The Royal College of Physicians
| - |
Marc Kaptein | M | - |
Impatients NV
Impatients NV Miscellaneous Commercial ServicesCommercial Services Impatients N.V. operates an online platform for drug innovations. It provides physicians and patients that are excluded from clinical trials access to drugs in development via early access programs. The company was founded by Ronald Brus, SJaak Vink, Govert J. Schouten, Witt Jan, Erdem Yavuz, and René Beukema in 2012 and is headquartered in Amsterdam, the United Kingdom. | - |
Stephen D. Wise | M | - |
The Royal College of Physicians
| - |
Allan Mark Watson | M | 57 |
Kyowa Kirin Ltd.
Kyowa Kirin Ltd. Pharmaceuticals: MajorHealth Technology Founded in 1998, Kyowa Kirin Ltd. is a British pharmaceutical company that develops, manufactures, and distributes pharmaceutical products. Part of Kirin Holdings Co., Ltd., the company is based in London, UK. | - |
Kemal Malik | M | 61 |
The Royal College of Physicians
| - |
Swee Huat Phua | M | 70 |
The Royal College of Physicians
| - |
David Schenkein | M | 66 |
Leyden Laboratories B.V.
Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | - |
Caroline Dumas | M | - |
The Royal College of Physicians
| - |
Simon Long | M | - |
The Royal College of Physicians
| - |
Sean Clayton | M | 45 | 2 ans | |
Kim Heung Tan | M | 62 |
The Royal College of Physicians
| 35 ans |
Ramesh Kancharla | M | 62 |
The Royal College of Physicians
| - |
Kwok Yiu Wong | M | 65 |
The Royal College of Physicians
| 38 ans |
Lindsey Rolfe | M | 56 |
The Royal College of Physicians
| - |
Hilary McElwaine-Johnn | M | - |
The Royal College of Physicians
| - |
Sanjay Rajpara | M | - |
The Royal College of Physicians
| - |
Andrew Richard Rut | M | 63 |
The Royal College of Physicians
| - |
Ik King Tiong | M | 74 |
The Royal College of Physicians
| 47 ans |
Kei Siong Khoo | M | 62 |
The Royal College of Physicians
| - |
Cheok Peng Lim | M | 77 |
The Royal College of Physicians
| 47 ans |
Suyash Prasad | M | 54 |
The Royal College of Physicians
| - |
Guido du Pree | M | - |
Impatients NV
Impatients NV Miscellaneous Commercial ServicesCommercial Services Impatients N.V. operates an online platform for drug innovations. It provides physicians and patients that are excluded from clinical trials access to drugs in development via early access programs. The company was founded by Ronald Brus, SJaak Vink, Govert J. Schouten, Witt Jan, Erdem Yavuz, and René Beukema in 2012 and is headquartered in Amsterdam, the United Kingdom. | - |
Martin Edwards | M | 68 |
The Royal College of Physicians
| - |
Keng Hwang Teh | M | 71 |
The Royal College of Physicians
| - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Alfred Mann | M | 98 | 25 ans | |
Paul Sekhri | M | 66 |
Cerimon Pharmaceuticals, Inc.
Cerimon Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Cerimon Pharmaceuticals, Inc. developed and distributed biopharmaceutical products. It developed Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, included pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. The company was founded by Paul J. Sekhri, Ansbert Gadicke, and Luke Evnin in November 2004 and was headquartered in South San Francisco, CA.
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | 5 ans |
William Burns | M | 76 |
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | 6 ans |
Matthew Pfeffer | M | 67 | 9 ans | |
Hakan S. Edstrom | M | 74 | 14 ans | |
Henri A. Termeer | M | 78 | 5 ans | |
Beth Taylor | F | 59 | 8 ans | |
Philip Hampton | M | 70 | 4 ans | |
Thomas Taapken | M | 59 | 3 ans | |
Duane DeSisto | M | 69 | 1 ans | |
Aaron Cox | M | 41 | 7 ans | |
Barry Moze | M | 70 | 8 ans | |
H. Culp | M | 60 | 9 ans | |
Balbir Kelly Bisla | F | - | 4 ans | |
Brian Beeler | M | 51 | 9 ans | |
Robert Metz | M | - | 10 ans | |
Jing Ulrich | F | 56 | - | |
Stevenson Ward | M | 78 |
Sterling Winthrop, Inc.
Sterling Winthrop, Inc. Electronics/AppliancesConsumer Durables Part of GSK Plc, Sterling Winthrop, Inc. is a company that specializes in cameras and duplicating machines. The company is based in Rochester, NY. Sterling Winthrop was acquired by GSK Plc from Eastman Kodak Co. on November 03, 1994 for $2,930 million. | 2 ans |
Gino Santini | M | 66 | 11 ans | |
Paul Hoelscher | M | 59 | 8 ans | |
H. Watkins | M | 71 | 9 ans | |
Lynn Elsenhans | F | 68 | 10 ans | |
Ronald E. Pauli | M | 63 | 8 ans | |
Jeff Himawan | M | 59 | 16 ans | |
Michael Grey | M | 71 | 12 ans | |
William Daniel | M | 72 | 9 ans | |
Gerardus Johannes Wijers | M | 74 | 3 ans | |
William John Jenkins | M | 77 |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | - |
Christopher Gent | M | 75 | 11 ans | |
Robert Wilson | M | 81 | 11 ans | |
Crispin Davis | M | 75 | 10 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Royaume-Uni | 47 | 47,00% |
Etats-Unis | 20 | 20,00% |
Pays-Bas | 18 | 18,00% |
Irlande | 14 | 14,00% |
Finlande | 3 | 3,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- James Shannon
- Réseau Personnel